top glp 1 companies GLP-1 Analogues Transform Metabolic Disease Management | Mahesh Malhotra posted on the topic GLP-1 Agonists Market Report 2025-2033,

Staying current with peptide research and studies helps you follow the evolving evidence base

Overall, all 5 studies displayed a low risk of bias

If phase 3 results remain positive, regulatory submissions may begin in 2026, meaning orforglipron could become available in late 2026 or 2027, depending on MHRA and NICE approval timelines

[DOI] [PubMed] [Google Scholar] 30.Cataland S, Crockett SE, Brown JC, Mazzaferri EL (1974) Gastric inhibitory polypeptide (GIP) stimulation by oral glucose in man

It shows promise for treating various substance use disorders and is generating significant excitement in the addiction medicine field